Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Thoracic Neoplasms 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × necitumumab × Clear all
NCT02392507 2020-11-19

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Eli Lilly and Company

Phase 2 Completed
54 enrolled 16 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡